BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050
Debt
Debt-to-Equity Ratio35.82
Current Ratio1.40
Quick Ratio1.13
Price-To-Earnings
Trailing P/E Ratio-7.95
Forward P/E Ratio-4.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$61.99 million
Price / Sales2.97
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book19.38
Profitability
EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins-122.75%
Return on Equity-388.58%
Return on Assets-61.59%
Miscellaneous
Employees116
Outstanding Shares59,340,000
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The specialty pharmaceutical company earned $11.28 million during the quarter, compared to the consensus estimate of $10.77 million. BioDelivery Sciences International had a negative net margin of 122.75% and a negative return on equity of 388.58%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
6 equities research analysts have issued twelve-month price objectives for BioDelivery Sciences International's stock. Their predictions range from $3.50 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.25 in the next year. View Analyst Ratings for BioDelivery Sciences International.
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. HC Wainwright analysts commented, "Helm With Wind in Belbuca’s Sails; Reiterate Buy Stock Data 05/04/2018 Price $1.93 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.85 Enterprise Value (M) $146.4 Market Cap (M) $108 Shares Outstanding (M) 55.9 3 Month Avg Volume 373,600 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAY-17 SEP-17 JAN-18 MAY-18 3 2.5 2 1.5 1 0.5 0 Vol. (mil) Price New CEO finally announced. BDSI announced the appointment of new CEO, Herm Cukier, ahead 1Q18 results reporting Thursday, May 10. Mr." (5/7/2018)
- 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) BDSI announced it had secured preferred coverage for Belbuca with Humana (HUM, Neutral) effective March 1. Effective Jan. 1, 2018, United Healthcare (UNH, OW) removed step edits for Belbuca, and CVS/Caremark (CVS, Not covered) and ProCareRx moved Belbuca to a preferred position. Additionally, Belbuca and Butrans have been added to the Ohio Workers Comp formulary as preferred medications, effective 4/1/18; 2) Belbuca prescriptions grew 10% in 4Q17 vs. 3Q17, and have continued to grow in 2018; 3) Scott Plesha was appointed to the role of President; and 4) cash and equivalents totaled $21.9MM at 12/31/17, which should fund operations into 2H18. Management noted on the call that it could potentially qualify for an additional tranche of its loan agreement in 2018. Other levers the company has to decrease cash burn and extend the cash runway include better-than- expected sales, lower R&D and SG&A spending, and potential partnerships or divestments of the company’s other products." (3/15/2018)
- 3. According to Zacks Investment Research, "BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market." (2/14/2018)
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Adamas Pharmaceuticals (ADMS), Odonate Therapeutics (ODT), GlycoMimetics (GLYC), Progenics Pharmaceuticals (PGNX), Insys Therapeutics (INSY), Kura Oncology (KURA), Akebia Therapeutics (AKBA), Aclaris Therapeutics (ACRS), Geron (GERN), Five Prime Therapeutics (FPRX), Aduro BioTech (ADRO), Keryx Biopharmaceuticals (KERX), Prothena (PRTA), Beyondspring (BYSI) and ChemoCentryx (CCXI).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Dr. Francis E. O'Donnell Jr., M.D., Exec. Chairman (Age 68)
- Dr. Mark A. Sirgo, Vice Chairman & Interim CEO (Age 64)
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
- Dr. Niraj Vasisht, CTO & Sr. VP of Product Devel. (Age 54)
- Mr. Scott M. Plesha, Pres
Has BioDelivery Sciences International been receiving favorable news coverage?
Headlines about BDSI stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 0.13 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (9.17%), BROADFIN CAPITAL, LLC (7.30%), BROADFIN CAPITAL, LLC (7.30%), BROADFIN CAPITAL, LLC (7.30%), Blair William & Co. IL (1.10%) and Hikari Power Ltd (0.86%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.
Which major investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Bailard Inc., Hikari Power Ltd and A.R.T. Advisors LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which major investors are buying BioDelivery Sciences International stock?
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $3.10.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $172.10 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
